The Federal Trade Commission has issued an Opinion and Order mandating that Illumina, a DNA sequencing provider, divest GRAIL, which produces a multi-cancer early detection (MCED) test. The decision was made because the acquisition was deemed detrimental for competition and innovation in the U.S. market for cancer tests. The Opinion overturns a previous ruling by an Administrative Law Judge who dismissed the antitrust allegations in a complaint filed by FTC staff.
Read more: Illumina Defends $7.1Billion Grail Buy At FTC Hearing
GRAIL creates non-invasive liquid biopsy tests that can detect various types of cancer in asymptomatic patients using DNA sequencing. It is competing with other companies in the race for these kinds of tests. Illumina is the leading producer of next-generation sequencing platforms, which are used in analyzing genetic material from blood samples for MCED tests. These tests could potentially detect several types of cancer that aren’t commonly screened for currently.
The Commission determined that the acquisition would have negative effects on innovation, prices, and options for MCED tests in the U.S. market. This is worrisome considering the urgency of developing efficient and reasonably-priced cancer detection tools.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI